SAN DIEGO--(BUSINESS WIRE)--Sapient, a leading biomarker discovery organization providing at scale services for multi-omics data generation and analysis, has announced the appointment of Jonathan Usuka, PhD, MBA as Chief Business Officer, expanding its leadership team to support and further propel the company’s rapid growth. In this role, Dr. Usuka will lead Sapient’s global business strategy for commercial collaborations, strategic partnerships, and client service innovations across its proteomic and metabolomic offerings leveraging Sapient’s Human Biology Database, the company’s industry leading real-world data asset. He will be the driving force in identifying new opportunities to serve therapeutic clients with Sapient’s large-scale multi-omics lab and unique data capabilities to enable advances in disease prediction, drug development, diagnostics, and personalized treatments for patients. “We are absolutely thrilled to welcome Jonathan into this critical leadership role for Sapient,” said Mo Jain, MD, PhD, Founder and CEO of Sapient. “He is a rare talent possessing both deep scientific acumen and extensive experience in business development and growth strategy, particularly in applying data and informatics to accelerate biopharma RD

SAN DIEGO--(BUSINESS WIRE)--Sapient, a biomarker discovery organization providing bespoke services for multi-omics data generation and analysis, has announced the roll-out of its high throughput discovery proteomics services, enabling measure of thousands of proteins in blood and tissue across diverse biological pathways. This offering further extends Sapient’s capabilities for dynamic biomarker discovery, utilizing its state-of-the-art mass spectrometry-based platform, which also powers its discovery metabolomics and lipidomics approaches.“We are particularly excited to extend Sapient’s offerings to include discovery proteomics,” said Jeramie Watrous, PhD, Co-Founder and Head of Analytical R&D at Sapient. “Measuring the proteome, particularly in blood, is a balance of protein depth and throughput. There are a number of approaches currently on the market for large-scale proteomics, and each of these has their own limitations, whether it be in the number of proteins that are assayed, the capture of proteoforms, the robustness of protein annotation, or in extension across varied species. We wanted to ensure our discovery proteomics offering could meet the varied demands of our biopharma and academic customers and provide a clear solution to each of these critical challenges, in line with the development phase or specific study objectives. In multiple matrices, including preclinical and clinical samples, we can generate data on thousands of proteins across thousands of samples, and integrate that data with other omics information to amplify biomarker discovery potential.”Mass spectrometry achieves high analytical specificity by directly measuring peptides to annotate proteins and post-translational modifications (PTMs)

The grant from Bill & Melinda Gates Foundation supports studies to identify biomarkers that inform novel disease prevention & treatment interventions.